Cerus (NASDAQ:CERS) is scheduled to issue its quarterly earnings data after the market closes on Thursday, November 1st. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.
Cerus (NASDAQ:CERS) last posted its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. The company had revenue of $15.42 million during the quarter, compared to the consensus estimate of $13.58 million. Cerus had a negative return on equity of 82.60% and a negative net margin of 76.37%. The firm’s quarterly revenue was up 61.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.16) EPS. On average, analysts expect Cerus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
CERS stock opened at $6.27 on Tuesday. The company has a quick ratio of 4.57, a current ratio of 5.03 and a debt-to-equity ratio of 0.29. The firm has a market cap of $853.73 million, a PE ratio of -11.20 and a beta of 1.51. Cerus has a fifty-two week low of $2.75 and a fifty-two week high of $8.05.
A number of brokerages have weighed in on CERS. BidaskClub lowered shares of Cerus from a “sell” rating to a “strong sell” rating in a research report on Friday, October 12th. Zacks Investment Research lowered shares of Cerus from a “buy” rating to a “hold” rating in a research report on Monday, August 6th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Cerus in a report on Thursday, August 2nd. Finally, Cowen set a $10.00 price objective on shares of Cerus and gave the stock a “buy” rating in a report on Friday, August 3rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $8.00.
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.
Featured Article: Does the discount rate affect the economy?
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.